Drug Pricing Center
![pills-943764_1920[1]](https://eadn-wc03-6094147.nxedge.io/wp-content/uploads/2015/01/pills-943764_19201-1500x430.jpg)
Resources
Five Years of State Action to Lower Drug Prices: 2017-2021, May 2021
Pharmacy Cost Work Group MembersEd Achuck, Pharmacy Section Chief, California Department of General Services
Susan Barrett, Executive Director, Green Mountain Care Board, Vermont
Burl Beasley, Director, Pharmacy Services, Oklahoma Office of Management and Enterprise Services
Terry Cothran, Senior Pharmacy Director, Oklahoma Health Care Authority
James DeBenedetti, Director of Plan Management, Covered California
Richard Gottfried, State Assemblyman and Chair of Committee on Health, New York State Assembly, District 75
Kaha Hizanishvili, Chief, Provider and Pharmacy Programs, MassHealth, Massachussetts Executive Office of Health and Human Services
Sonya Jaquez Lewis, State Senator, Colorado State Senate, District 17
Eileen Mallow, Director, Office of Strategic Health Policy, Wisconsin Department of Employee Trust Funds
Kevin Martin, Pharmacy Rates Analyst, Colorado Department of Health Care Policy and Financing
Sara Sadownik, Deputy Director, Research and Cost Trends, Massachusetts Health Policy Commission
David Seltz, Executive Director, Massachusetts Health Policy Commission
Tricia Sieg, Pharmacy Benefit Program Manager, Wisconsin Department of Employee Trust Funds
Donna Sullivan, Chief Pharmacy Officer, Washington State Health Care Authority
Norman Thurston, State Representative, Utah House of Representatives, District 64
Joshua Wojcik, Assistant Comptroller, Connecticut Office of the Comptroller
Andrew York, Executive Director, Maryland Prescription Drug Affordability Board
To learn more about the Center or to receive state-only materials contact Jennifer Reck (jreck@oldsite.nashp.org)
Sign Up for Our Weekly Newsletter
Sign Up for Our Weekly Newsletter
Washington, DC Office:
1233 20th St., N.W., Suite 303Washington, DC 20036
p: (202) 903-0101
f: (202) 903-2790
Contact Us
Phone: 202-903-0101

For individuals living with complex, often chronic conditions, and their families, palliative care can provide relief from symptoms, improve satisfaction and outcomes, and help address critical mental and spiritual needs during difficult times. Now more than ever, there is growing recognition of the importance of palliative care services for individuals with serious illness, such as advance care planning, pain and symptom management, care coordination, and team-based, multi-disciplinary support. These services can help patients and families cope with the symptoms and stressors of disease, better anticipate and avoid crises, and reduce unnecessary and/or unwanted care. While this model is grounded in evidence that demonstrates improved quality of life, better outcomes, and reduced cost for patients, only a fraction of individuals who could benefit from palliative care receive it. 
























































































































































The State of States’ Health Policies: What Governors Highlighted in their 2019 Addresses
/in Policy Blogs Behavioral/Mental Health and SUD, Care Coordination, Chronic and Complex Populations, Chronic Disease Prevention and Management, Cost, Payment, and Delivery Reform, Health Coverage and Access, Health Equity, Health System Costs, Housing and Health, Maternal, Child, and Adolescent Health, Medicaid Expansion, Medicaid Managed Care, Medicaid Managed Care, Population Health, Prescription Drug Pricing, Social Determinants of Health, State Insurance Marketplaces, State Rx Legislative Action, Value-Based Purchasing /by Anita CardwellState of the state and inaugural speeches give governors the opportunity to highlight their recent policy successes and outline key plans and priorities for the coming year. These speeches are strong indicators of governors’ policy goals and often include proposals and funding recommendations for their legislatures. As a result of 2018 gubernatorial races in 36 […]
Annual Federal Insurance Rule Includes Proposals to Address Prescription Drug Cost
/in Policy Blogs Administrative Actions, Cost, Payment, and Delivery Reform, Health Coverage and Access, Health System Costs, Prescription Drug Pricing, State Insurance Marketplaces, State Rx Legislative Action /by Sarah Lanford and Maureen Hensley-QuinnThe Trump Administration’s effort to address drug prices surfaced unexpectedly in the Department of Health and Human Services (HHS)’s recently issued proposed annual rule that regulates state health insurance markets, including coverage sold through the Affordable Care Act (ACA) marketplaces. The proposal encourages the use of generic drugs over brand-name drugs by both health plans and enrollees […]
The Case for State Action on Health Prices in 12 Slides
/in Policy Blogs Cost, Payment, and Delivery Reform, Health System Costs, Making the Case for Action, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffIn the last few months, NASHP has convened state leaders in two summits that addressed rising health care costs. With assistance from Larry Levitt of the Kaiser Family Foundation and Erin Fuse Brown of Georgia State University College of Law, NASHP compiled a slide presentation documenting the factors behind the health care cost trajectory to […]
Guest Blog: Massachusetts Report Recommends More Health Care Price Transparency and Simpler Payment Methods
/in Policy Massachusetts Blogs Administrative Actions, Cost, Payment, and Delivery Reform, Health System Costs, Hospital/Health System Oversight, Prescription Drug Pricing, Quality and Measurement, State Rx Legislative Action, Value-Based Purchasing /by Amara Azubuike and Sandra WolitzkyAmara Azubuike and Sandra Wolitzky are assistant attorneys general in the Massachusetts Office of the Attorney General. A new report released in October 2018 by Massachusetts Attorney General Maura Healey finds that complicated and varied methods used to determine health care payment rates contribute to administrative cost increases and make it difficult for market participants […]
Deadline Looms for State Comments on Fed’s Latest Insurance Rules
/in Policy Blogs Eligibility and Enrollment, Health Coverage and Access, Prescription Drug Pricing, State Insurance Marketplaces /by NASHP StaffAfter a delay, the Department of Health and Human Services (HHS) has issued its proposed annual rule regulating state health insurance markets, including coverage sold through the Affordable Care Act (ACA) marketplaces. View NASHP’s chart highlighting the rule’s provisions that impact states here. The deadline to submit comments on the rule is Feb. 19, 2019. […]
New Tools Help States Document Rx Costs and Identify Potential Savings
/in Policy Maine Blogs Administrative Actions, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffJust how much are states spending on prescription drugs? And, which drugs account for their greatest expense? As state policymakers grapple with solutions to the problem of rising drug costs, officials are performing research to provide critical evidence and tools needed to inform policy. Two recent state efforts to document their prescription drug costs may […]
As State Legislatures Convene, Lawmakers Quickly Submit Bills to Curb Prescription Prices
/in Policy Blogs Administrative Actions, Legislative Tracker, Prescription Drug Pricing, State Rx Legislative Action /by Sarah LanfordOne week into the 2019 legislative season, lawmakers from 11 states have already submitted 30 bills to address the rising cost of prescription drugs. The bills submitted to date seek to implement wholesale drug importation programs, increase pharmaceutical pricing transparency, and regulate pharmacy benefit managers (PBMs), along with other drug cost containment initiatives. Last year, […]
Q&A: Do Medicaid Alternative Payment Models for Prescription Drugs Add Value for States?
/in Policy Oklahoma Administrative Actions, Cost, Payment, and Delivery Reform, Health Coverage and Access, Medicaid Managed Care, Prescription Drug Pricing /by NASHP WritersIn late December, 2018, the National Academy for State Health Policy (NASHP) hosted a webinar exploring Oklahoma Medicaid agency’s use of innovative alternative payment models (APMs) through contracts negotiated with drug manufacturers, which link supplemental rebates to patient outcomes. The webinar, Medicaid Alternative Payment Models for Prescription Drugs: Do They Add Value for States?, featured […]
NASHP Applauds Vermont for Taking Next Step in Prescription Drug Importation
/in Policy Vermont Blogs Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by NASHP WritersFOR IMMEDIATE RELEASE Thursday, January 3, 2019 The Vermont Agency for Human Services has presented its report on wholesale importation of prescription drugs from Canada as required by the state’s legislature pursuant to a law enacted last year. The National Academy for State Health Policy (NASHP), with a team of consultants including FDAImports.com, LLC and […]
As Drug Prices Rise, Oklahoma’s Medicaid Agency Advances Alternative Payment Models
/in Policy Oklahoma Blogs Administrative Actions, Cost, Payment, and Delivery Reform, Health System Costs, Medicaid Managed Care, Prescription Drug Pricing, Quality and Measurement, Value-Based Purchasing /by Jennifer ReckEscalating drug prices are forcing state Medicaid agencies to explore new payment models. According to Burl Beasley, director of Pharmacy Services for Oklahoma’s Medicaid program, older Medicaid payment strategies, such as negotiating enhanced rebates and multi-state purchase agreements, are not keeping pace with rising drug expenditures. Beasley cited the strain prescription drug costs were putting […]